An experimental non-hormonal treatment for menopause was rejected by a Food and Drug Administration advisory panel this week because the group found risks associated with the drug were greater than any benefit it offered. Drug maker Depomed submitted for approval Seflsa, known generically as gabapentin, a medication that has long been used to treat pain and seizures. It is also prescribed off-label by doctors to treat menopause symptoms. Depomed asked the FDA to approve this use, which would allow the company to market it as a menopause treatment. The panel’s decision to vote against approving Seflsa is based on studies that ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.